/ Source

Food and Drugs Act

Primary federal statute for food, drugs, cosmetics, and medical devices.

Last evidence check means this project’s automated public-repository check; it is not a government audit, regulator audit, external audit, or assurance engagement.

Justice Laws Website, Government of CanadaofficialLast evidence check 2026-05-05Accessed 2026-05-05Open original Back to source library

Source statusJustice Laws Website, Government of Canada source record checked 2026-05-05

Review trailSource usage is tied to public topics and claim records in the repository.

Source typeofficial

Topics using source1

Claims referenced4

Why this source matters

Baseline source for What would happen to prescription drug approvals, safety recalls, and medicine supply? This record currently supports 1 topic and 4 claims in the public repository.

Evidence details

This source row records the publisher, source type, reliability label, access date, original URL, and any archive copy available to this project.

Used by topics

001Would prescription drug approvals, recalls, and medicine supply still work?Current sources show federal legal and regulatory baselines for drug approval, safety, compliance, recalls, and health-product information; independence would require explicit continuity plans for medicine access, safety surveillance, and supply chains.

Referenced claims

001pharmaceutical-drug-approvals-supplyCurrent sources establish Canadian legal and regulatory baselines for drug approvals, safety alerts, compliance, enforcement, recalls, and health-product information, but not Alberta independence transition terms.

002pharmaceutical-drug-approvals-supplyA credible transition would need explicit arrangements for recognizing approvals, labelling, recalls, adverse-event reporting, import rules, pharmacy guidance, manufacturer guidance, and supply continuity.

003pharmaceutical-drug-approvals-supplyThe pro-independence case is strongest if Alberta can preserve current medicine access through recognition and supply bridges before attempting local regulatory redesign.

004pharmaceutical-drug-approvals-supplyThe anti-independence caution is strongest because medicine safety requires trusted legal authority, regulator capacity, recall channels, and supply-chain clarity before patients can rely on continuity.